ID   MK09_HUMAN              Reviewed;         424 AA.
AC   P45984; A8K0S3; B5BU66; B5M0B4; D3DWQ8; D3DWQ9; Q15708; Q15710; Q15711;
AC   Q8N5C5;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2006, sequence version 2.
DT   12-OCT-2022, entry version 224.
DE   RecName: Full=Mitogen-activated protein kinase 9;
DE            Short=MAP kinase 9;
DE            Short=MAPK 9;
DE            EC=2.7.11.24 {ECO:0000269|PubMed:11062067, ECO:0000269|PubMed:15805466, ECO:0000269|PubMed:17875713, ECO:0000269|PubMed:21110917, ECO:0000269|PubMed:7969172, ECO:0000269|PubMed:8001819, ECO:0000269|PubMed:8654373};
DE   AltName: Full=JNK-55;
DE   AltName: Full=Stress-activated protein kinase 1a;
DE            Short=SAPK1a;
DE   AltName: Full=Stress-activated protein kinase JNK2;
DE   AltName: Full=c-Jun N-terminal kinase 2;
GN   Name=MAPK9; Synonyms=JNK2, PRKM9, SAPK1A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CATALYTIC ACTIVITY.
RX   PubMed=7969172; DOI=10.1128/mcb.14.12.8376-8384.1994;
RA   Sluss H.K., Barrett T., Derijard B., Davis R.J.;
RT   "Signal transduction by tumor necrosis factor mediated by JNK protein
RT   kinases.";
RL   Mol. Cell. Biol. 14:8376-8384(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CATALYTIC ACTIVITY.
RX   PubMed=8001819; DOI=10.1101/gad.8.24.2996;
RA   Kallunki T., Su B., Tsigelny I., Sluss H.K., Derijard B., Moore G.,
RA   Davis R., Karin M.;
RT   "JNK2 contains a specificity-determining region responsible for efficient
RT   c-Jun binding and phosphorylation.";
RL   Genes Dev. 8:2996-3007(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], ALTERNATIVE SPLICING, AND CATALYTIC ACTIVITY.
RC   TISSUE=Brain;
RX   PubMed=8654373; DOI=10.1002/j.1460-2075.1996.tb00636.x;
RA   Gupta S., Barrett T., Whitmarsh A.J., Cavanagh J., Sluss H.K., Derijard B.,
RA   Davis R.J.;
RT   "Selective interaction of JNK protein kinase isoforms with transcription
RT   factors.";
RL   EMBO J. 15:2760-2770(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), AND CATALYTIC ACTIVITY.
RX   PubMed=21110917; DOI=10.5483/bmbrep.2010.43.11.738;
RA   Wang P., Xiong Y., Ma C., Shi T., Ma D.;
RT   "Molecular cloning and characterization of novel human JNK2 (MAPK9)
RT   transcript variants that show different stimulation activities on AP-1.";
RL   BMB Rep. 43:738-743(2010).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P.,
RA   Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y.,
RA   LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BETA-2).
RC   TISSUE=Amygdala;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ALA-268.
RG   NIEHS SNPs program;
RL   Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-2).
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y.,
RA   Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A.,
RA   Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y.,
RA   Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T.,
RA   Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y.,
RA   Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S.,
RA   Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in vitro-
RT   expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   INTERACTION WITH ATF7, AND FUNCTION.
RX   PubMed=10376527; DOI=10.1038/sj.onc.1202723;
RA   De Graeve F., Bahr A., Sabapathy K.T., Hauss C., Wagner E.F., Kedinger C.,
RA   Chatton B.;
RT   "Role of the ATFa/JNK2 complex in Jun activation.";
RL   Oncogene 18:3491-3500(1999).
RN   [13]
RP   PHOSPHORYLATION AT THR-183 AND TYR-185, REGULATION BY MAP2K4 AND MAP2K7,
RP   CATALYTIC ACTIVITY, AND COFACTOR.
RX   PubMed=11062067; DOI=10.1042/bj3520145;
RA   Fleming Y., Armstrong C.G., Morrice N., Paterson A., Goedert M., Cohen P.;
RT   "Synergistic activation of stress-activated protein kinase 1/c-Jun N-
RT   terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase
RT   kinase 4 (MKK4) and MKK7.";
RL   Biochem. J. 352:145-154(2000).
RN   [14]
RP   INTERACTION WITH SPAG9.
RX   PubMed=15693750; DOI=10.1042/bj20041577;
RA   Jagadish N., Rana R., Selvi R., Mishra D., Garg M., Yadav S., Herr J.C.,
RA   Okumura K., Hasegawa A., Koyama K., Suri A.;
RT   "Characterization of a novel human sperm-associated antigen 9 (SPAG9)
RT   having structural homology with c-Jun N-terminal kinase-interacting
RT   protein.";
RL   Biochem. J. 389:73-82(2005).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF RRN3, AND CATALYTIC ACTIVITY.
RX   PubMed=15805466; DOI=10.1101/gad.333205;
RA   Mayer C., Bierhoff H., Grummt I.;
RT   "The nucleolus as a stress sensor: JNK2 inactivates the transcription
RT   factor TIF-IA and down-regulates rRNA synthesis.";
RL   Genes Dev. 19:933-941(2005).
RN   [16]
RP   INTERACTION WITH NFATC4, AND CATALYTIC ACTIVITY.
RX   PubMed=17875713; DOI=10.1158/0008-5472.can-06-4788;
RA   Yao K., Cho Y.-Y., Bergen H.R. III, Madden B.J., Choi B.Y., Ma W.-Y.,
RA   Bode A.M., Dong Z.;
RT   "Nuclear factor of activated T3 is a negative regulator of Ras-JNK1/2-AP-1
RT   induced cell transformation.";
RL   Cancer Res. 67:8725-8735(2007).
RN   [17]
RP   INTERACTION WITH BCL10, AND CATALYTIC ACTIVITY.
RX   PubMed=17189706; DOI=10.1016/j.immuni.2006.11.008;
RA   Blonska M., Pappu B.P., Matsumoto R., Li H., Su B., Wang D., Lin X.;
RT   "The CARMA1-Bcl10 signaling complex selectively regulates JNK2 kinase in
RT   the T cell receptor-signaling pathway.";
RL   Immunity 26:55-66(2007).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF TP53, AND CATALYTIC ACTIVITY.
RX   PubMed=17525747; DOI=10.1038/sj.onc.1210526;
RA   Oleinik N.V., Krupenko N.I., Krupenko S.A.;
RT   "Cooperation between JNK1 and JNK2 in activation of p53 apoptotic
RT   pathway.";
RL   Oncogene 26:7222-7230(2007).
RN   [19]
RP   REVIEW ON FUNCTION.
RX   PubMed=19290929; DOI=10.1111/j.1600-065x.2008.00749.x;
RA   Blonska M., Lin X.;
RT   "CARMA1-mediated NF-kappaB and JNK activation in lymphocytes.";
RL   Immunol. Rev. 228:199-211(2009).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [21]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CTNNB1.
RX   PubMed=19675674; DOI=10.1371/journal.pone.0006640;
RA   Hu D., Bi X., Fang W., Han A., Yang W.;
RT   "GSK3beta is involved in JNK2-mediated beta-catenin inhibition.";
RL   PLoS ONE 4:E6640-E6640(2009).
RN   [22]
RP   FUNCTION.
RX   PubMed=20595622; DOI=10.1152/ajpgi.00265.2010;
RA   Samak G., Suzuki T., Bhargava A., Rao R.K.;
RT   "c-Jun NH2-terminal kinase-2 mediates osmotic stress-induced tight junction
RT   disruption in the intestinal epithelium.";
RL   Am. J. Physiol. 299:G572-G584(2010).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF YAP1, AND CATALYTIC ACTIVITY.
RX   PubMed=21364637; DOI=10.1038/cddis.2010.7;
RA   Tomlinson V., Gudmundsdottir K., Luong P., Leung K.Y., Knebel A., Basu S.;
RT   "JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis.";
RL   Cell Death Dis. 1:E29-E29(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=22441692; DOI=10.1038/embor.2012.37;
RA   Yoshitane H., Honma S., Imamura K., Nakajima H., Nishide S.Y., Ono D.,
RA   Kiyota H., Shinozaki N., Matsuki H., Wada N., Doi H., Hamada T., Honma K.,
RA   Fukada Y.;
RT   "JNK regulates the photic response of the mammalian circadian clock.";
RL   EMBO Rep. 13:455-461(2012).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.14 ANGSTROMS) OF 7-362.
RX   PubMed=18801372; DOI=10.1016/j.jmb.2008.08.086;
RA   Shaw D., Wang S.M., Villasenor A.G., Tsing S., Walter D., Browner M.F.,
RA   Barnett J., Kuglstatter A.;
RT   "The crystal structure of JNK2 reveals conformational flexibility in the
RT   MAP kinase insert and indicates its involvement in the regulation of
RT   catalytic activity.";
RL   J. Mol. Biol. 383:885-893(2008).
RN   [27]
RP   VARIANTS [LARGE SCALE ANALYSIS] MET-13; ASN-56; THR-246 AND ILE-366.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [28]
RP   INTERACTION WITH MAPKBP1.
RX   PubMed=28089251; DOI=10.1016/j.ajhg.2016.12.011;
RA   Macia M.S., Halbritter J., Delous M., Bredrup C., Gutter A., Filhol E.,
RA   Mellgren A.E., Leh S., Bizet A., Braun D.A., Gee H.Y., Silbermann F.,
RA   Henry C., Krug P., Bole-Feysot C., Nitschke P., Joly D., Nicoud P.,
RA   Paget A., Haugland H., Brackmann D., Ahmet N., Sandford R., Cengiz N.,
RA   Knappskog P.M., Boman H., Linghu B., Yang F., Oakeley E.J.,
RA   Saint Mezard P., Sailer A.W., Johansson S., Roedahl E., Saunier S.,
RA   Hildebrandt F., Benmerah A.;
RT   "Mutations in MAPKBP1 cause juvenile or late-onset cilia-independent
RT   nephronophthisis.";
RL   Am. J. Hum. Genet. 100:323-333(2017).
RN   [29]
RP   ERRATUM OF PUBMED:28089251.
RX   PubMed=28157543; DOI=10.1016/j.ajhg.2017.01.025;
RA   Macia M.S., Halbritter J., Delous M., Bredrup C., Gutter A., Filhol E.,
RA   Mellgren A.E., Leh S., Bizet A., Braun D.A., Gee H.Y., Silbermann F.,
RA   Henry C., Krug P., Bole-Feysot C., Nitschke P., Joly D., Nicoud P.,
RA   Paget A., Haugland H., Brackmann D., Ahmet N., Sandford R., Cengiz N.,
RA   Knappskog P.M., Boman H., Linghu B., Yang F., Oakeley E.J.,
RA   Saint Mezard P., Sailer A.W., Johansson S., Roedahl E., Saunier S.,
RA   Hildebrandt F., Benmerah A.;
RL   Am. J. Hum. Genet. 100:372-372(2017).
CC   -!- FUNCTION: Serine/threonine-protein kinase involved in various processes
CC       such as cell proliferation, differentiation, migration, transformation
CC       and programmed cell death. Extracellular stimuli such as pro-
CC       inflammatory cytokines or physical stress stimulate the stress-
CC       activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling
CC       pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and
CC       MAP2K7/MKK7 phosphorylate and activate MAPK9/JNK2. In turn, MAPK9/JNK2
CC       phosphorylates a number of transcription factors, primarily components
CC       of AP-1 such as JUN and ATF2 and thus regulates AP-1 transcriptional
CC       activity. In response to oxidative or ribotoxic stresses, inhibits rRNA
CC       synthesis by phosphorylating and inactivating the RNA polymerase 1-
CC       specific transcription initiation factor RRN3. Promotes stressed cell
CC       apoptosis by phosphorylating key regulatory factors including TP53 and
CC       YAP1. In T-cells, MAPK8 and MAPK9 are required for polarized
CC       differentiation of T-helper cells into Th1 cells. Upon T-cell receptor
CC       (TCR) stimulation, is activated by CARMA1, BCL10, MAP2K7 and
CC       MAP3K7/TAK1 to regulate JUN protein levels. Plays an important role in
CC       the osmotic stress-induced epithelial tight-junctions disruption. When
CC       activated, promotes beta-catenin/CTNNB1 degradation and inhibits the
CC       canonical Wnt signaling pathway. Participates also in neurite growth in
CC       spiral ganglion neurons. Phosphorylates the CLOCK-ARNTL/BMAL1
CC       heterodimer and plays a role in the regulation of the circadian clock
CC       (PubMed:22441692). Phosphorylates POU5F1, which results in the
CC       inhibition of POU5F1's transcriptional activity and enhances its
CC       proteosomal degradation (By similarity). {ECO:0000250|UniProtKB:Q9WTU6,
CC       ECO:0000269|PubMed:22441692}.
CC   -!- FUNCTION: MAPK9 isoforms display different binding patterns: alpha-1
CC       and alpha-2 preferentially bind to JUN, whereas beta-1 and beta-2 bind
CC       to ATF2. However, there is no correlation between binding and
CC       phosphorylation, which is achieved at about the same efficiency by all
CC       isoforms. JUNB is not a substrate for JNK2 alpha-2, and JUND binds only
CC       weakly to it.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.24;
CC         Evidence={ECO:0000269|PubMed:11062067, ECO:0000269|PubMed:15805466,
CC         ECO:0000269|PubMed:17189706, ECO:0000269|PubMed:17525747,
CC         ECO:0000269|PubMed:17875713, ECO:0000269|PubMed:21110917,
CC         ECO:0000269|PubMed:21364637, ECO:0000269|PubMed:22441692,
CC         ECO:0000269|PubMed:7969172, ECO:0000269|PubMed:8001819,
CC         ECO:0000269|PubMed:8654373};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.24; Evidence={ECO:0000269|PubMed:11062067,
CC         ECO:0000269|PubMed:15805466, ECO:0000269|PubMed:17189706,
CC         ECO:0000269|PubMed:17525747, ECO:0000269|PubMed:17875713,
CC         ECO:0000269|PubMed:21110917, ECO:0000269|PubMed:21364637,
CC         ECO:0000269|PubMed:22441692, ECO:0000269|PubMed:7969172,
CC         ECO:0000269|PubMed:8001819, ECO:0000269|PubMed:8654373};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:11062067};
CC   -!- ACTIVITY REGULATION: Activated by threonine and tyrosine
CC       phosphorylation by either of two dual specificity kinases, MAP2K4 and
CC       MAP2K7. MAP2K4 shows a strong preference for Tyr-185 while MAP2K7
CC       phosphorylates Tyr-183 preferentially. Inhibited by dual specificity
CC       phosphatases, such as DUSP1. {ECO:0000269|PubMed:11062067}.
CC   -!- SUBUNIT: Interacts with MECOM (By similarity). Interacts with DCLK2 (By
CC       similarity). Binds to at least four scaffolding proteins, MAPK8IP1/JIP-
CC       1, MAPK8IP2/JIP-2, MAPK8IP3/JIP-3/JSAP1 and SPAG9/MAPK8IP4/JIP-4. These
CC       proteins also bind other components of the JNK signaling pathway (By
CC       similarity). Interacts with NFATC4 (PubMed:17875713). Interacts with
CC       ATF7; the interaction does not phosphorylate ATF7 but acts as a docking
CC       site for ATF7-associated partners such as JUN (PubMed:10376527).
CC       Interacts with BCL10 (PubMed:17189706). Interacts with CTNNB1 and GSK3B
CC       (PubMed:19675674). Interacts with MAPKBP1 (PubMed:28089251). Interacts
CC       with POU5F1; phosphorylates POU5F1 at 'Ser-355'. Found in a complex
CC       with SH3RF1, RAC2, MAP3K7/TAK1, MAP2K7/MKK7, MAPK8IP1/JIP1 and
CC       MAPK8/JNK1 (By similarity). {ECO:0000250|UniProtKB:P49186,
CC       ECO:0000250|UniProtKB:Q9WTU6, ECO:0000269|PubMed:10376527,
CC       ECO:0000269|PubMed:17189706, ECO:0000269|PubMed:17875713,
CC       ECO:0000269|PubMed:19675674, ECO:0000269|PubMed:28089251}.
CC   -!- INTERACTION:
CC       P45984; P49407: ARRB1; NbExp=9; IntAct=EBI-713568, EBI-743313;
CC       P45984; P32121: ARRB2; NbExp=9; IntAct=EBI-713568, EBI-714559;
CC       P45984; P15336: ATF2; NbExp=9; IntAct=EBI-713568, EBI-1170906;
CC       P45984; P0C671: BNIP5; NbExp=3; IntAct=EBI-713568, EBI-12806802;
CC       P45984; O95561: C1orf105; NbExp=5; IntAct=EBI-713568, EBI-10191951;
CC       P45984; Q6P1W5: C1orf94; NbExp=3; IntAct=EBI-713568, EBI-946029;
CC       P45984; Q8N7E2: CBLL2; NbExp=3; IntAct=EBI-713568, EBI-12196065;
CC       P45984; Q13042: CDC16; NbExp=3; IntAct=EBI-713568, EBI-994830;
CC       P45984; Q9C0F1: CEP44; NbExp=9; IntAct=EBI-713568, EBI-744115;
CC       P45984; Q13363-2: CTBP1; NbExp=3; IntAct=EBI-713568, EBI-10171858;
CC       P45984; O43602-2: DCX; NbExp=3; IntAct=EBI-713568, EBI-14148644;
CC       P45984; Q8N9I9: DTX3; NbExp=3; IntAct=EBI-713568, EBI-2340258;
CC       P45984; Q9Y6W6: DUSP10; NbExp=5; IntAct=EBI-713568, EBI-3443946;
CC       P45984; Q9BY84: DUSP16; NbExp=7; IntAct=EBI-713568, EBI-3443956;
CC       P45984; Q13115: DUSP4; NbExp=4; IntAct=EBI-713568, EBI-6591081;
CC       P45984; Q5JST6: EFHC2; NbExp=7; IntAct=EBI-713568, EBI-2349927;
CC       P45984; Q9H0I2: ENKD1; NbExp=3; IntAct=EBI-713568, EBI-744099;
CC       P45984; P14136: GFAP; NbExp=3; IntAct=EBI-713568, EBI-744302;
CC       P45984; Q9NYA3: GOLGA6A; NbExp=3; IntAct=EBI-713568, EBI-11163335;
CC       P45984; O15499: GSC2; NbExp=3; IntAct=EBI-713568, EBI-19954058;
CC       P45984; Q8IYA8: IHO1; NbExp=3; IntAct=EBI-713568, EBI-8638439;
CC       P45984; Q13352: ITGB3BP; NbExp=3; IntAct=EBI-713568, EBI-712105;
CC       P45984; Q9P2G9-2: KLHL8; NbExp=3; IntAct=EBI-713568, EBI-11959635;
CC       P45984; O00505: KPNA3; NbExp=3; IntAct=EBI-713568, EBI-358297;
CC       P45984; Q96JM7: L3MBTL3; NbExp=3; IntAct=EBI-713568, EBI-2686809;
CC       P45984; Q96JM7-2: L3MBTL3; NbExp=3; IntAct=EBI-713568, EBI-11985629;
CC       P45984; Q9UBR4-2: LHX3; NbExp=3; IntAct=EBI-713568, EBI-12039345;
CC       P45984; Q8TBB1: LNX1; NbExp=7; IntAct=EBI-713568, EBI-739832;
CC       P45984; Q8N448: LNX2; NbExp=3; IntAct=EBI-713568, EBI-2340947;
CC       P45984; Q9Y250: LZTS1; NbExp=3; IntAct=EBI-713568, EBI-1216080;
CC       P45984; Q96EZ8: MCRS1; NbExp=3; IntAct=EBI-713568, EBI-348259;
CC       P45984; Q86YW9: MED12L; NbExp=3; IntAct=EBI-713568, EBI-3957138;
CC       P45984; P50221: MEOX1; NbExp=7; IntAct=EBI-713568, EBI-2864512;
CC       P45984; Q5VWP3-2: MLIP; NbExp=5; IntAct=EBI-713568, EBI-12320785;
CC       P45984; Q5HYW2: NHSL2; NbExp=5; IntAct=EBI-713568, EBI-2859639;
CC       P45984; Q02548: PAX5; NbExp=3; IntAct=EBI-713568, EBI-296331;
CC       P45984; Q9BYU1: PBX4; NbExp=3; IntAct=EBI-713568, EBI-10302990;
CC       P45984; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-713568, EBI-79165;
CC       P45984; P78424: POU6F2; NbExp=3; IntAct=EBI-713568, EBI-12029004;
CC       P45984; P37231: PPARG; NbExp=3; IntAct=EBI-713568, EBI-781384;
CC       P45984; Q96S79: RASL10B; NbExp=3; IntAct=EBI-713568, EBI-3919507;
CC       P45984; Q2I0M5: RSPO4; NbExp=3; IntAct=EBI-713568, EBI-12821217;
CC       P45984; Q8IYX7: SAXO1; NbExp=3; IntAct=EBI-713568, EBI-3957636;
CC       P45984; O00560: SDCBP; NbExp=3; IntAct=EBI-713568, EBI-727004;
CC       P45984; Q15427: SF3B4; NbExp=7; IntAct=EBI-713568, EBI-348469;
CC       P45984; P34896: SHMT1; NbExp=7; IntAct=EBI-713568, EBI-715117;
CC       P45984; A2RU48: SMCO3; NbExp=6; IntAct=EBI-713568, EBI-10173195;
CC       P45984; P40763: STAT3; NbExp=2; IntAct=EBI-713568, EBI-518675;
CC       P45984; Q8TDR4: TCP10L; NbExp=3; IntAct=EBI-713568, EBI-3923210;
CC       P45984; Q8IYF3: TEX11; NbExp=3; IntAct=EBI-713568, EBI-742397;
CC       P45984; Q8IYF3-3: TEX11; NbExp=3; IntAct=EBI-713568, EBI-11523345;
CC       P45984; O43379: WDR62; NbExp=5; IntAct=EBI-713568, EBI-714790;
CC       P45984; Q53FD0-2: ZC2HC1C; NbExp=3; IntAct=EBI-713568, EBI-14104088;
CC       P45984; P52744: ZNF138; NbExp=3; IntAct=EBI-713568, EBI-10746567;
CC       P45984; Q9BR84: ZNF559; NbExp=3; IntAct=EBI-713568, EBI-746605;
CC       P45984; O43257: ZNHIT1; NbExp=3; IntAct=EBI-713568, EBI-347522;
CC       P45984-1; P40763: STAT3; NbExp=3; IntAct=EBI-713586, EBI-518675;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:19675674}. Nucleus
CC       {ECO:0000269|PubMed:19675674}. Note=Colocalizes with POU5F1 in the
CC       nucleus. {ECO:0000250|UniProtKB:Q9WTU6}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=Alpha-2;
CC         IsoId=P45984-1; Sequence=Displayed;
CC       Name=Alpha-1;
CC         IsoId=P45984-2; Sequence=VSP_004835;
CC       Name=Beta-1;
CC         IsoId=P45984-3; Sequence=VSP_004834, VSP_004835;
CC       Name=Beta-2;
CC         IsoId=P45984-4; Sequence=VSP_004834;
CC       Name=5;
CC         IsoId=P45984-5; Sequence=VSP_041908, VSP_041909;
CC   -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues
CC       whose phosphorylation activates the MAP kinases.
CC   -!- PTM: Dually phosphorylated on Thr-183 and Tyr-185 by MAP2K7 and MAP2K4,
CC       which activates the enzyme. Autophosphorylated in vitro.
CC       {ECO:0000269|PubMed:11062067}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. MAP kinase subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/JNK2ID426.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/mapk9/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L31951; AAA56831.1; -; mRNA.
DR   EMBL; U09759; AAA74740.1; -; mRNA.
DR   EMBL; U34821; AAC50606.1; -; mRNA.
DR   EMBL; U35002; AAC50608.1; -; mRNA.
DR   EMBL; U35003; AAC50609.1; -; mRNA.
DR   EMBL; EU927388; ACH57450.1; -; mRNA.
DR   EMBL; CR536580; CAG38817.1; -; mRNA.
DR   EMBL; AK289638; BAF82327.1; -; mRNA.
DR   EMBL; DQ066599; AAY46156.1; -; Genomic_DNA.
DR   EMBL; AB451302; BAG70116.1; -; mRNA.
DR   EMBL; AB451355; BAG70169.1; -; mRNA.
DR   EMBL; AC008610; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104115; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471165; EAW53759.1; -; Genomic_DNA.
DR   EMBL; CH471165; EAW53757.1; -; Genomic_DNA.
DR   EMBL; CH471165; EAW53758.1; -; Genomic_DNA.
DR   EMBL; CH471165; EAW53762.1; -; Genomic_DNA.
DR   EMBL; BC032539; AAH32539.1; -; mRNA.
DR   CCDS; CCDS43409.1; -. [P45984-2]
DR   CCDS; CCDS43410.1; -. [P45984-3]
DR   CCDS; CCDS4453.1; -. [P45984-1]
DR   CCDS; CCDS4454.1; -. [P45984-4]
DR   CCDS; CCDS47356.1; -. [P45984-5]
DR   PIR; A55480; A55480.
DR   PIR; S71102; S71102.
DR   RefSeq; NP_001128516.1; NM_001135044.1. [P45984-5]
DR   RefSeq; NP_001295173.1; NM_001308244.1.
DR   RefSeq; NP_002743.3; NM_002752.4. [P45984-1]
DR   RefSeq; NP_620707.1; NM_139068.2. [P45984-2]
DR   RefSeq; NP_620708.1; NM_139069.2. [P45984-3]
DR   RefSeq; NP_620709.1; NM_139070.2. [P45984-4]
DR   RefSeq; XP_006714954.1; XM_006714891.2.
DR   RefSeq; XP_016865127.1; XM_017009638.1.
DR   RefSeq; XP_016865130.1; XM_017009641.1.
DR   PDB; 3E7O; X-ray; 2.14 A; A/B=7-362.
DR   PDB; 3NPC; X-ray; 2.35 A; A/B=1-364.
DR   PDB; 7CML; X-ray; 2.15 A; A/B=1-364.
DR   PDBsum; 3E7O; -.
DR   PDBsum; 3NPC; -.
DR   PDBsum; 7CML; -.
DR   AlphaFoldDB; P45984; -.
DR   SMR; P45984; -.
DR   BioGRID; 111587; 170.
DR   DIP; DIP-270N; -.
DR   ELM; P45984; -.
DR   IntAct; P45984; 105.
DR   MINT; P45984; -.
DR   STRING; 9606.ENSP00000394560; -.
DR   BindingDB; P45984; -.
DR   ChEMBL; CHEMBL4179; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB15624; Halicin.
DR   DrugBank; DB01017; Minocycline.
DR   DrugBank; DB07020; N-{3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]phenyl}furan-2-carboxamide.
DR   DrugCentral; P45984; -.
DR   GuidetoPHARMACOLOGY; 1497; -.
DR   GlyConnect; 1515; 1 N-Linked glycan (1 site).
DR   GlyGen; P45984; 2 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site).
DR   iPTMnet; P45984; -.
DR   MetOSite; P45984; -.
DR   PhosphoSitePlus; P45984; -.
DR   BioMuta; MAPK9; -.
DR   DMDM; 85700366; -.
DR   REPRODUCTION-2DPAGE; P45984; -.
DR   CPTAC; CPTAC-893; -.
DR   CPTAC; CPTAC-894; -.
DR   EPD; P45984; -.
DR   jPOST; P45984; -.
DR   MassIVE; P45984; -.
DR   MaxQB; P45984; -.
DR   PaxDb; P45984; -.
DR   PeptideAtlas; P45984; -.
DR   PRIDE; P45984; -.
DR   ProteomicsDB; 55698; -. [P45984-1]
DR   ProteomicsDB; 55699; -. [P45984-2]
DR   ProteomicsDB; 55700; -. [P45984-3]
DR   ProteomicsDB; 55701; -. [P45984-4]
DR   ProteomicsDB; 55702; -. [P45984-5]
DR   Antibodypedia; 4557; 916 antibodies from 46 providers.
DR   DNASU; 5601; -.
DR   Ensembl; ENST00000343111.10; ENSP00000345524.6; ENSG00000050748.18. [P45984-3]
DR   Ensembl; ENST00000393360.7; ENSP00000377028.3; ENSG00000050748.18. [P45984-2]
DR   Ensembl; ENST00000425491.6; ENSP00000397422.2; ENSG00000050748.18. [P45984-5]
DR   Ensembl; ENST00000452135.7; ENSP00000394560.2; ENSG00000050748.18. [P45984-1]
DR   Ensembl; ENST00000455781.5; ENSP00000389338.1; ENSG00000050748.18. [P45984-4]
DR   GeneID; 5601; -.
DR   KEGG; hsa:5601; -.
DR   MANE-Select; ENST00000452135.7; ENSP00000394560.2; NM_002752.5; NP_002743.3.
DR   UCSC; uc003mls.5; human. [P45984-1]
DR   CTD; 5601; -.
DR   DisGeNET; 5601; -.
DR   GeneCards; MAPK9; -.
DR   HGNC; HGNC:6886; MAPK9.
DR   HPA; ENSG00000050748; Low tissue specificity.
DR   MIM; 602896; gene.
DR   neXtProt; NX_P45984; -.
DR   OpenTargets; ENSG00000050748; -.
DR   PharmGKB; PA30630; -.
DR   VEuPathDB; HostDB:ENSG00000050748; -.
DR   eggNOG; KOG0665; Eukaryota.
DR   GeneTree; ENSGT00940000158327; -.
DR   HOGENOM; CLU_000288_181_1_1; -.
DR   InParanoid; P45984; -.
DR   OMA; IESVGNW; -.
DR   OrthoDB; 741207at2759; -.
DR   PhylomeDB; P45984; -.
DR   TreeFam; TF105100; -.
DR   BRENDA; 2.7.11.24; 2681.
DR   PathwayCommons; P45984; -.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; R-HSA-450341; Activation of the AP-1 family of transcription factors.
DR   SignaLink; P45984; -.
DR   SIGNOR; P45984; -.
DR   BioGRID-ORCS; 5601; 8 hits in 1112 CRISPR screens.
DR   ChiTaRS; MAPK9; human.
DR   EvolutionaryTrace; P45984; -.
DR   GeneWiki; Mitogen-activated_protein_kinase_9; -.
DR   GenomeRNAi; 5601; -.
DR   Pharos; P45984; Tchem.
DR   PRO; PR:P45984; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P45984; protein.
DR   Bgee; ENSG00000050748; Expressed in middle temporal gyrus and 212 other tissues.
DR   ExpressionAtlas; P45984; baseline and differential.
DR   Genevisible; P45984; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004705; F:JUN kinase activity; IDA:UniProtKB.
DR   GO; GO:0004707; F:MAP kinase activity; IBA:GO_Central.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IEA:Ensembl.
DR   GO; GO:0097190; P:apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0071276; P:cellular response to cadmium ion; IMP:CAFA.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IMP:CAFA.
DR   GO; GO:0090398; P:cellular senescence; TAS:Reactome.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0007254; P:JNK cascade; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:CAFA.
DR   GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL.
DR   GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0071803; P:positive regulation of podosome assembly; IEA:Ensembl.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IEA:Ensembl.
DR   GO; GO:1901485; P:positive regulation of transcription factor catabolic process; IEA:Ensembl.
DR   GO; GO:0061833; P:protein localization to tricellular tight junction; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0051090; P:regulation of DNA-binding transcription factor activity; TAS:Reactome.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR003527; MAP_kinase_CS.
DR   InterPro; IPR008351; MAPK_JNK.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR01772; JNKMAPKINASE.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01351; MAPK; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Biological rhythms;
KW   Cytoplasm; Kinase; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..424
FT                   /note="Mitogen-activated protein kinase 9"
FT                   /id="PRO_0000186273"
FT   DOMAIN          26..321
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          368..424
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           183..185
FT                   /note="TXY"
FT   COMPBIAS        376..416
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        151
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         32..40
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         55
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         183
FT                   /note="Phosphothreonine; by MAP2K7"
FT                   /evidence="ECO:0000269|PubMed:11062067"
FT   MOD_RES         185
FT                   /note="Phosphotyrosine; by MAP2K4"
FT                   /evidence="ECO:0000269|PubMed:11062067"
FT   VAR_SEQ         216..230
FT                   /note="GELVKGCVIFQGTDH -> AEMVLHKVLFPGRDY (in isoform
FT                   Beta-1 and isoform Beta-2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_004834"
FT   VAR_SEQ         230..242
FT                   /note="HIDQWNKVIEQLG -> RILPRDLGPAMLS (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:21110917"
FT                   /id="VSP_041908"
FT   VAR_SEQ         243..424
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:21110917"
FT                   /id="VSP_041909"
FT   VAR_SEQ         378..424
FT                   /note="DAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPLEGCR -> A
FT                   QMQQ (in isoform Alpha-1 and isoform Beta-1)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_004835"
FT   VARIANT         13
FT                   /note="V -> M (in a colorectal adenocarcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042260"
FT   VARIANT         56
FT                   /note="K -> N (in a head & Neck squamous cell carcinoma
FT                   sample; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042261"
FT   VARIANT         246
FT                   /note="A -> T (in dbSNP:rs35421153)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042262"
FT   VARIANT         268
FT                   /note="G -> A (in dbSNP:rs35693958)"
FT                   /evidence="ECO:0000269|Ref.7"
FT                   /id="VAR_025175"
FT   VARIANT         366
FT                   /note="R -> I (in dbSNP:rs55736180)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042263"
FT   CONFLICT        51
FT                   /note="N -> S (in Ref. 1; AAA56831 and 3;
FT                   AAC50606/AAC50608/AAC50609)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        377
FT                   /note="S -> P (in Ref. 2; AAA74740)"
FT                   /evidence="ECO:0000305"
FT   TURN            6..8
FT                   /evidence="ECO:0007829|PDB:7CML"
FT   STRAND          10..15
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   STRAND          18..23
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   STRAND          26..33
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   STRAND          38..45
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   TURN            46..49
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   STRAND          50..58
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   HELIX           60..62
FT                   /evidence="ECO:0007829|PDB:7CML"
FT   HELIX           64..79
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   STRAND          88..92
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   TURN            98..100
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   STRAND          105..109
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   STRAND          112..114
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   HELIX           115..118
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   HELIX           125..144
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   HELIX           154..156
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   STRAND          157..159
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   STRAND          165..167
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   TURN            176..178
FT                   /evidence="ECO:0007829|PDB:3NPC"
FT   STRAND          180..183
FT                   /evidence="ECO:0007829|PDB:3NPC"
FT   HELIX           189..191
FT                   /evidence="ECO:0007829|PDB:7CML"
FT   HELIX           194..197
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   HELIX           206..220
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   HELIX           232..241
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   HELIX           246..250
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   HELIX           254..261
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   HELIX           271..274
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   HELIX           277..279
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   HELIX           286..301
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   HELIX           306..308
FT                   /evidence="ECO:0007829|PDB:7CML"
FT   HELIX           312..316
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   HELIX           319..322
FT                   /evidence="ECO:0007829|PDB:3E7O"
FT   HELIX           327..330
FT                   /evidence="ECO:0007829|PDB:7CML"
FT   TURN            341..343
FT                   /evidence="ECO:0007829|PDB:3NPC"
FT   HELIX           349..360
FT                   /evidence="ECO:0007829|PDB:3E7O"
SQ   SEQUENCE   424 AA;  48139 MW;  9C15DA79981290AF CRC64;
     MSDSKCDSQF YSVQVADSTF TVLKRYQQLK PIGSGAQGIV CAAFDTVLGI NVAVKKLSRP
     FQNQTHAKRA YRELVLLKCV NHKNIISLLN VFTPQKTLEE FQDVYLVMEL MDANLCQVIH
     MELDHERMSY LLYQMLCGIK HLHSAGIIHR DLKPSNIVVK SDCTLKILDF GLARTACTNF
     MMTPYVVTRY YRAPEVILGM GYKENVDIWS VGCIMGELVK GCVIFQGTDH IDQWNKVIEQ
     LGTPSAEFMK KLQPTVRNYV ENRPKYPGIK FEELFPDWIF PSESERDKIK TSQARDLLSK
     MLVIDPDKRI SVDEALRHPY ITVWYDPAEA EAPPPQIYDA QLEEREHAIE EWKELIYKEV
     MDWEERSKNG VVKDQPSDAA VSSNATPSQS SSINDISSMS TEQTLASDTD SSLDASTGPL
     EGCR
//
